KenvueKVUEEarnings & Financial Report
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.
Revenue
$3.7B
Gross Profit
$2.1B
Operating Profit
$483.0M
Net Profit
$293.0M
Gross Margin
56.5%
Operating Margin
13.2%
Net Margin
8.0%
YoY Growth
-6.5%
EPS
$0.16
Kenvue Q4 FY2024 Financial Summary
Kenvue reported revenue of $3.7B (down 6.5% YoY) for Q4 FY2024, with a net profit of $293.0M (down 33.1% YoY) (8.0% margin). Cost of goods sold was $1.6B, operating expenses totaled $1.6B.
Key Financial Metrics
| Total Revenue | $3.7B |
|---|---|
| Net Profit | $293.0M |
| Gross Margin | 56.5% |
| Operating Margin | 13.2% |
| Report Period | Q4 FY2024 |
Revenue Breakdown
Kenvue Q4 FY2024 revenue of $3.7B breaks down across 3 segments, led by Self Care at $1.6B (42.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Self Care | $1.6B | 42.8% |
| Essential Health | $1.1B | 29.5% |
| Skin Health And Beauty | $1.0B | 27.6% |
Kenvue Revenue by Segment — Quarterly Trend
Kenvue revenue by segment across the last 4 reported quarters, showing how each business line (such as Self Care and Essential Health) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Self Care | $1.6B | $1.6B | $1.6B | $1.7B |
| Essential Health | $1.1B | $1.2B | $1.2B | $1.1B |
| Skin Health And Beauty | $1.0B | $1.0B | $1.1B | $977.0M |
Kenvue Annual Revenue by Year
Kenvue annual revenue history includes year-by-year totals (for example, 2025 revenue was $15.1B).
| Year | Annual Revenue |
|---|---|
| 2025 | $15.1B |
| 2024 | $15.5B |
Kenvue Quarterly Revenue & Net Profit History
Kenvue results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $3.8B | +3.2% | $330.0M | 8.7% |
| Q3 FY2025 | $3.8B | -3.5% | $398.0M | 10.6% |
| Q2 FY2025 | $3.8B | -4.0% | $420.0M | 10.9% |
| Q1 FY2025 | $3.7B | -3.9% | $322.0M | 8.6% |
| Q4 FY2024 | $3.7B | -6.5% | $293.0M | 8.0% |
| Q3 FY2024 | $3.9B | -2.8% | $383.0M | 9.8% |
| Q2 FY2024 | $4.0B | +3.8% | $58.0M | 1.5% |
| Q1 FY2024 | $3.9B | +3.4% | $296.0M | 7.6% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.89B | $4.00B | $3.90B | $3.66B | $3.74B | $3.84B | $3.76B | $3.78B |
| YoY Growth | 3.4% | 3.8% | -2.8% | -6.5% | -3.9% | -4.0% | -3.5% | 3.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $27.28B | $26.44B | $26.93B | $25.60B | $26.26B | $27.13B | $27.25B | $27.08B |
| Liabilities | $16.66B | $16.27B | $16.28B | $15.93B | $16.20B | $16.40B | $16.61B | $16.31B |
| Equity | $10.62B | $10.18B | $10.64B | $9.67B | $10.05B | $10.73B | $10.63B | $10.77B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $287.0M | $440.0M | $249.0M | $793.0M | $428.0M | $621.0M | $294.0M | $854.0M |